Stocktoria
AbbVie Inc. ABBV
AbbVie Inc. (ABBV) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 2.60% (safety: at-risk). FY2025 revenue was $61.2B at a 6.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.85 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-11 | BNP Paribas | Neutral (main) |
| 2026-08-10 | Evercore ISI Group | Outperform (main) |
| 2026-08-04 | Guggenheim | Buy (main) |
| 2026-08-03 | Canaccord Genuity | Buy (main) |
| 2026-08-03 | Cantor Fitzgerald | Overweight (main) |
| 2026-07-29 | Barclays | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.106 |
| Retained earnings / assets | -0.116 |
| EBIT / assets | 0.113 |
| Equity / liabilities | -0.024 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
| ABT | ABBOTT LABORATORIES | 5/9 | 4.85 | 25.1 | +5.7% |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
FAQ
Is ABBV financially healthy?
AbbVie Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ABBV pay a dividend, and is it safe?
Yes. AbbVie Inc. pays a dividend yielding about 2.60% with a 275.8% payout ratio, rated “at-risk” for safety.
How profitable is ABBV?
In FY2025, AbbVie Inc. had a net margin of 6.9%.
Is ABBV overvalued or undervalued?
AbbVie Inc. trades at about 105.4× trailing earnings — above its 10-year norm (10-year range 15.3×–94.5×, median 34.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ABBV?
The average Wall-Street price target for AbbVie Inc. is $275.39, about 10.7% above the recent price, from 28 analysts (consensus: buy).
Is ABBV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AbbVie Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the distress zone, a P/E of about 105.9×, a dividend yield of 2.60%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.